CYP 2.50% 19.5¢ cynata therapeutics limited

Ann: Ethics Approval & Expedited Pathway for Phase 3 OA Trial, page-9

  1. 174 Posts.
    lightbulb Created with Sketch. 85
    I wonder if the market understands the enormity of this news.... A phase 3 trial that is essentially no cost to CYP and they retain the full rights to the product..... with a market in the billions
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.